Lucid Diagnostics (LUCD) Net Equity Issued and Repurchased (2023 - 2024)

Lucid Diagnostics (LUCD) posted Net Equity Issued and Repurchased of $1.8 million for Q1 2024, up 18.73% on a QoQ basis from $1.5 million in Q3 2023, and up 533.8% year-over-year from $284000.0 in Q2 2023.

Lucid Diagnostics (LUCD) Net Equity Issued and Repurchased (2023 - 2024) Analysis & Trends

Lucid Diagnostics' Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $1.8 million for Q1 2024.

  • Quarterly Net Equity Issued and Repurchased rose 533.8% year-over-year to $1.8 million in Q1 2024, while the trailing twelve-month figure through Mar 2026 was $1.8 million (changed 0.0% YoY) and the FY2025 annual result came in at $274000.0, changed N/A from the prior year.
  • Net Equity Issued and Repurchased was $1.8 million for Q1 2024 at Lucid Diagnostics, up from $1.5 million in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $1.8 million in Q1 2024 and bottomed at $284000.0 in Q1 2023.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn -
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn -
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 97.00 Mn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn -
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 12.70 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn -
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn -
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Lucid Diagnostics 133.09 Mn 105.22 Mn -325,000.00 -

Historic Data

Download Data
DateValue
Mar 31, 2024 1.80 Mn
Mar 31, 2024 1.80 Mn
Sep 30, 2023 1.52 Mn
Sep 30, 2023 1.52 Mn
Mar 31, 2023 284,000.00
Mar 31, 2023 284,000.00